Discover a wide selection of tumor and cancer models in oncology
Oncodesign Services, a CRO specialized in Drug Discovery, offers a range of discovery and preclinical services built upon cancer models of syngeneic, cell-derived xenograft (CDX) and patient-derived xenograft (PDX) tumors.
With individual or integrated studies, we contribute to the discovery of innovatives therapies against cancer.
Standard readouts in oncology
◈ Tumor size
◈ Liquid biopsy
◈ Protein expression
◈ Cytokine/biomarker expression (by LBA)
◈ TIL fractions (by flow/FACS)
◈ Histology
◈ Conservation of phenotype and genotype
◈ Gene expression stability
◈ Gene mutation status
◈ Response to standard of care (SOC)
Integrated CRO services in Oncology
Oncodesign Services encompasses all preclinical services to deliver cancer drug candidates including:
1
Medicinal Chemistry
Medicinal Chemistry for Oncology
2
Bioanalysis
Bioanalysis for Oncology
Oncodesign Services offers formulation, immunogenicity and bioanalytical sample analysis services including platforms for small molecules (NCEs), peptides, large molecules (NBEs), monoclonal antibodies (mAb), Antibody-Drug Conjugates (ADC), Anti-Drug Antibodies (ADA), Neutralizing Antibodies (Nab), oligonucleotides (OGN) and biomarkers (simplex/multiplex).
3
In vitro biology
4
Pharmaco-Imaging
5
DMPK
6
In vivo pharmacology
In vivo pharmacology for Oncology
From its inception, Oncodesign Services has dedicated efforts to centralize skills, assays and expertise to conduct complete preclinical pharmacological characterization of drugs in the field of oncology, immunology, immune-inflammation or infectious diseases. Our multi-disciplinary team keeps your program moving quickly by providing proof of concept for your lead compounds.
Medicinal Chemistry for Oncology
Bioanalysis for Oncology
Oncodesign Services offers formulation, immunogenicity and bioanalytical sample analysis services including platforms for small molecules (NCEs), peptides, large molecules (NBEs), monoclonal antibodies (mAb), Antibody-Drug Conjugates (ADC), Anti-Drug Antibodies (ADA), Neutralizing Antibodies (Nab), oligonucleotides (OGN) and biomarkers (simplex/multiplex).
In vivo pharmacology for Oncology
From its inception, Oncodesign Services has dedicated efforts to centralize skills, assays and expertise to conduct complete preclinical pharmacological characterization of drugs in the field of oncology, immunology, immune-inflammation or infectious diseases. Our multi-disciplinary team keeps your program moving quickly by providing proof of concept for your lead compounds.
Who is Oncodesign Services?
Oncodesign Services is a Contract research organization (CRO) specializing in drug discovery and preclinical services. From target identification to IND filing, the company contributes to the development of innovative therapies in oncology, inflammation and infectious diseases, with high medical needs.
Oncodesign Services has 230 employees in France, Canada and the United States.
Any request ? Contact us for more information